AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 12 min read$TEM

LEFKOFSKY ERIC P sold $9.6M of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 166,250 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $57.48 ($55.38–$59.23, $9.56M total) across 10 trades on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LEFKOFSKY ERIC P
Published Jul 1, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TEM
Neutral
medium confidence
Mentioned
$TEM
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The newest actionable element is the disclosed sale size (~166,250 shares; ~$9.56M) and the stated 10b5-1 pre-arranged plan, which frames the transaction as planned rather than opportunistic.

02

Market read

Newly filed insider-sale data can influence short-term sentiment, but 10b5-1 labeling typically limits interpretive weight.

03

What to watch

Traders may overreact to insider sales; the key is whether subsequent filings show sales outside the planned schedule or changes in total insider ownership trend.

Relevance 5/10Novelty 6/10Timing: after-hours/next-session read-through from a newly filed Form 4 (filed 2026-07-01)

Background

The article is an SEC Form 4 insider transaction disclosure for Tempus AI, Inc. (TEM) by CEO/Chairman Eric P. Lefkofsky, executed across multiple trades on 2026-06-29.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI CEO/Chairman Eric P. Lefkofsky sold ~$9.56M of TEM shares via a 10b5-1 plan on 2026-06-29 at $55.38–$59.23.

Expected impact

Likely limited, short-lived sentiment impact; watch for follow-through only if selling accelerates beyond planned cadence.

Evidence & confidence

The filing is primary-source and time-stamped, but it explicitly states a pre-arranged 10b5-1 plan, which typically dampens interpretation as new negative information.

Market effects

Sector

Minimal; this is company-specific insider transaction with no sector-wide catalyst.

Regional

Minimal; no broader macro or regional linkage in the filing details.

Global

Minimal; no international deal/regulatory action described.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be routine liquidity management rather than a bearish signal.

Key entities

  • issuer
    Tempus AI, Inc.

    Subject of the Form 4 insider sale; CEO/Chairman Eric P. Lefkofsky sold shares under a 10b5-1 plan.

  • insider
    LEFKOFSKY ERIC P

    CEO and Chairman; sold 166,250 shares indirectly on 2026-06-29 at $55.38–$59.23 (weighted avg $57.482).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEM insider trading history →

Related articles

AUG 27
$TEMMedAI 9/10

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Tempus AI (TEM) shares rose after Moderna and Merck reported positive Phase 3 trial results for a personalized cancer therapy, validating Personalis' sequencing technology. Tempus agreed to acquire Personalis for $1.5B, with the deal pending. Personalis' technology is distinct from the main target of the acquisition, NeXT Personal, a tumor-informed molecular residual disease test. Tempus reported 9,000 MRD tests in Q2, while Personalis generated $22.357M in revenue and delivered 10,384 clinical

insidermonkey.com3 min
AUG 24
$TEMMedAI 8/10

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

Tempus AI, Inc. (NASDAQ: TEM) received FDA clearance for its AI product, Tempus ECG-PH, designed to detect signs of pulmonary hypertension from standard ECGs. This is the third FDA-cleared cardiovascular device in Tempus' portfolio, aiming to help clinicians identify at-risk patients earlier. The product analyzes ECG data but is not intended for standalone diagnosis.

biospace.com2 min
AUG 23
$TEMHighAI 8/10

Why Tempus AI Skyrocketed This Week

Tempus AI (TEM) shares rose 39.5% this week after Merck and Moderna reported positive Phase 3 trial data for their cancer vaccine, which uses technology from Personalis, a company Tempus is acquiring. Tempus's market cap is $13B, and its stock is still down about 10% over the past year. The acquisition is expected to close late 2024 or early 2027.

fool.com2 min
AUG 22
$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.

stockstotrade.com3 min